Vertex Pharmaceuticals Inc stock is traded at $525.76, with a volume of 246,468. It is down -1.99% in the last 24 hours and up +4.74% over the past month. Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Previous Close:
$536.45
Open:
$537.79
24h Volume:
246,468
Relative Volume:
0.19
Market Cap:
$133.30B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
31.17
EPS:
$16.87
Net Cash Flow:
$3.71B
1W Performance:
-3.11%
1M Performance:
+4.74%
6M Performance:
+21.06%
1Y Performance:
+24.87%
1-Day Range:
$522.29$537.79
1-Week Range:
$522.29$549.56
52-Week Range:
$412.27$568.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(617) 341-6393Address
50 NORTHERN AVENUE, BOSTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS